News
Article about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau
An article about our tuberculosis (TB) vaccine has been published in the “Frankfurter Rundschau”. For more info click here.
Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows
A clinical trial in South Africa has now shown that the new vaccine candidate VPM1002, developed by Max Planck researcher Stefan H.E. Kaufmann and his team, is equally safe for newborns with and without HIV exposure and has fewer side effects compared to BCG. Please click here to read the publication.
Milestone achieved: end of recruitment for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.
SAVE THE DATE: VPM & TWINCORE Joint Symposium | Sep 15-16, 2022 | Hannover
It is our pleasure to announce that the 14th TWINCORE Symposium and the 13th International VPM Days, celebrating VPM’s 20th Anniversary, will take place as a joint symposium “Lessons from the pandemic for future infection research” on Thursday and Friday, 15 and 16 September 2022 in Hannover, Germany.
Register here!
VPM at the OPTIMMUNIZE 2022 Meeting
VPM was invited guest speaker at the OPTIMMUNIZE 2022 which was held as webinar on April 21st. Watch the video here!
Prime update: visit to the East African clinical sites
We are pleased that after the long COVID lockdown we were also able to visit the East African sites to touch base and to discuss the conduct of the trial and potential improvements. We thank all centres for their warm welcome and their hospitality during our stay and hope to meet more often in person again.
VPM at the Immunotherapy for Infectious Diseases Conference – IIDC 2022
VPM will give a presentation as an invited guest speaker at the IMMUNOTHERAPY FOR INFECTIOUS DISEASES CONFERENCE – IIDC 2022 in Pavia (Italy), which will take place from June 20 to 23, 2022! Read more!
Delegation aus Ghana bei VPM
We have welcome the delegation from Ghana on February, 18 and had a fruitful conversation on vaccine development.
Results of SAKK 06/14 trial with VPM1002BC as treatment for non-muscle-invasive bladder cancer have been published in European Urology Oncology
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions. Please click here to read the publication.
priMe update: visit of the South African clinical sites
We are pleased that after the long COVID lockdown we were able to visit the south African sites to touch base and to discuss the conduct of the trial and potential improvements. We thanks all centres for their warm welcome and their hospitality during our stay and hope that, once everything is more or less back to normal, we’ll meet more often in person again.
